Payment overview · 2025
General Payments
$435.95
25 reported records · 9 companies
Healthcare provider profile · identity verified
Robert M Frederickson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1306955497
Verified facts
What the public records show
CMS Open Payments records show Robert M Frederickson, MD received $435.95 in general payments during 2025 across 25 reported records.
GlaxoSmithKline, LLC. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.99 | 19.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.85 | 16.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.84 | 15.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.19 | 13.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.69 | 11.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.78 | 8.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.02 | 6.9% | 2 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $20.82 | 4.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.77 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $435.95 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $86.99 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.85 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.85 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $63.37 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.19 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.69 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.48 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| IMMULITE 1000 Immunoassay System Normalized: immulite 1000 immunoassay system |
Device | Siemens Medical Solutions USA, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 124 |
| Losartan Potassium | Losartan Potassium | 310 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 81 |
| Omeprazole | Omeprazole | 188 | 59 |
| Simvastatin | Simvastatin | 177 | 51 |
| Clonazepam | Clonazepam | 167 | 38 |
| Potassium Chloride | Potassium Chloride | 150 | 45 |
| Ozempic | Semaglutide | 149 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 140 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 49 |
| Metformin Hcl | Metformin Hcl | 123 | 37 |
| Trazodone Hcl | Trazodone Hcl | 118 | 37 |
| Jardiance | Empagliflozin | 109 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 26 |
| Celecoxib | Celecoxib | 76 | 24 |
| Metformin Hcl Er | Metformin Hcl | 76 | 25 |
| Lisinopril | Lisinopril | 74 | 21 |
| Allopurinol | Allopurinol | 72 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 23 |
| Ezetimibe | Ezetimibe | 69 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 23 |
| Famotidine | Famotidine | 67 | 20 |
| Methocarbamol | Methocarbamol | 60 | 20 |
| Atenolol | Atenolol | 59 | 16 |
| Eliquis | Apixaban | 59 | suppressed |
| Meloxicam | Meloxicam | 58 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 14 |
| Sertraline Hcl | Sertraline Hcl | 46 | 14 |
| Alendronate Sodium | Alendronate Sodium | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Furosemide | Furosemide | 41 | 14 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Gabapentin | Gabapentin | 31 | 11 |
| Rybelsus | Semaglutide | 30 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Methylprednisolone | Methylprednisolone | 23 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Estradiol | Estradiol | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.95 · 25 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, IMMULITE 1000 Immunoassay System, KRYSTEXXA, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error